Astrazeneca PLC (NYSE:AZN)’s share price gapped up before the market opened on Friday . The stock had previously closed at $32.33, but opened at $32.60. Astrazeneca PLC shares last traded at $33.30, with a volume of 2,239,563 shares changing hands.

A number of brokerages recently commented on AZN. JPMorgan Chase & Co. restated a “neutral” rating on shares of Astrazeneca PLC in a report on Monday, August 8th. Cantor Fitzgerald restated a “buy” rating on shares of Astrazeneca PLC in a report on Monday, August 8th. Citigroup Inc. restated a “buy” rating on shares of Astrazeneca PLC in a report on Wednesday, August 10th. Shore Capital restated a “hold” rating on shares of Astrazeneca PLC in a report on Wednesday, August 10th. Finally, Beaufort Securities restated a “hold” rating on shares of Astrazeneca PLC in a report on Thursday, August 11th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. Astrazeneca PLC currently has a consensus rating of “Buy” and a consensus target price of $36.88.

The company has a market cap of $84.27 billion and a P/E ratio of 38.07. The firm’s 50-day moving average is $32.95 and its 200 day moving average is $30.09.

Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.76 by $0.07. The business earned $5.60 billion during the quarter, compared to analysts’ expectations of $5.56 billion. The company’s revenue for the quarter was down 4.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.21 EPS. Analysts predict that Astrazeneca PLC will post $2.97 earnings per share for the current fiscal year.

The firm also recently declared a dividend, which will be paid on Monday, September 12th. Investors of record on Friday, August 12th will be issued a $0.44 dividend. The ex-dividend date of this dividend is Wednesday, August 10th.

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.